CPI-1205

DRUG3 trials

Sponsors

Constellation Pharmaceuticals

Conditions

Advanced Solid TumorsB-Cell LymphomaMetastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 1

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

CompletedNCT02395601

Constellation PharmaceuticalsB-Cell Lymphoma

Start: 2015-03-31End: 2018-12-31Target: 41Updated: 2022-05-18

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

CompletedNCT03480646

Constellation PharmaceuticalsMetastatic Castration Resistant Prostate Cancer (mCRPC)

Start: 2017-11-15End: 2021-02-03Updated: 2025-10-29

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

CompletedNCT03525795

Constellation PharmaceuticalsAdvanced Solid Tumors

Start: 2017-12-14End: 2019-06-12Updated: 2022-05-18

Related Papers

ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2019-03-0116 citations